肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

欧洲推出Herceptin生物仿制药Herzuma

2018-05-04 MedSci MedSci原创

Herceptin生物仿制药Herzuma
关注

Mundipharma称其公司网络已经启动了Celltrion的Herceptin生物仿制药Herzuma在欧洲的推广。该产品的首个发布地是英国--Napp制药在英国拥有分销权，在德国也有，预计未来几个月还将推出更多产品。Mundipharma网络在英国，德国，意大利，爱尔兰，比利时，卢森堡和荷兰拥有Herzuma的独家经销权。Herzuma于3月份在欧洲通过了其原研药的所有适应症的使用，即用于治


Mundipharma称其公司网络已经启动了Celltrion的Herceptin生物仿制药Herzuma在欧洲的推广。
该产品的首个发布地是英国--Napp制药在英国拥有分销权，在德国也有，预计未来几个月还将推出更多产品。

Mundipharma网络在英国，德国，意大利，爱尔兰，比利时，卢森堡和荷兰拥有Herzuma的独家经销权。

Herzuma于3月份在欧洲通过了其原研药的所有适应症的使用，即用于治疗患有早期乳腺癌，转移性乳腺癌或具有HER2过表达或HER2基因扩增的转移性胃癌的患者。

Herceptin是由Genentech开发的一种生物药物，由罗氏公司(Roche)销售，2016年全球销售额达到68亿美元，其中21亿美元来自欧洲。

Mundipharma International的肿瘤学和生物仿制药主管Richard Trollope说："使用生物仿制药曲妥珠单抗将为全欧洲数千名合格的患者提供一种替代治疗方案。"

NHS英国医院规定的十大药物中有六种是生物制品。

通常情况下，生物仿制药比其原研药"便宜得多"， "如果NHS采用主动，系统和安全的方式使用更有价值的生物药品，NHS在2020/21年之前每年可能节省至少2亿至3亿英镑的成本。" Napp先前说。


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=333408, encodeId=43973334089b, content=不错的文章，值得学习和借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6R7YL2c7UHBd9dTQlxwPXnib6Ns6m6boxy2iaaXKuT8vNMCc9OnThlsMmtEicgwuMyMHTLhDE41ncldwBzHcgia0QQ/132, createdBy=c0982346683, createdName=余国法, createdTime=Sun Jul 22 16:30:59 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715775, encodeId=10ab1e15775e9, content=<a href='/topic/show?id=094a8e60b3' target=_blank style='color:#2F92EE;'>#Herzuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8760, encryptionId=094a8e60b3, topicName=Herzuma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=838832043195, createdName=gj0742, createdTime=Fri Mar 15 23:58:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313298, encodeId=4a013132985f, content=[, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Wed May 09 00:17:03 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339082, encodeId=35f613390822f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412911, encodeId=04091412911c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548181, encodeId=9bf5154818151, content=<a href='/topic/show?id=48b98e537f' target=_blank style='color:#2F92EE;'>#Herceptin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8753, encryptionId=48b98e537f, topicName=Herceptin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ecc14021123, createdName=minhuang75_72521588, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312454, encodeId=a550312454f3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 06 07:28:40 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312057, encodeId=79e531205efd, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri May 04 22:57:02 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312047, encodeId=cb5531204e10, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 04 22:36:58 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-07-22 余国法

    不错的文章，值得学习和借鉴

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=333408, encodeId=43973334089b, content=不错的文章，值得学习和借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6R7YL2c7UHBd9dTQlxwPXnib6Ns6m6boxy2iaaXKuT8vNMCc9OnThlsMmtEicgwuMyMHTLhDE41ncldwBzHcgia0QQ/132, createdBy=c0982346683, createdName=余国法, createdTime=Sun Jul 22 16:30:59 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715775, encodeId=10ab1e15775e9, content=<a href='/topic/show?id=094a8e60b3' target=_blank style='color:#2F92EE;'>#Herzuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8760, encryptionId=094a8e60b3, topicName=Herzuma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=838832043195, createdName=gj0742, createdTime=Fri Mar 15 23:58:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313298, encodeId=4a013132985f, content=[, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Wed May 09 00:17:03 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339082, encodeId=35f613390822f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412911, encodeId=04091412911c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548181, encodeId=9bf5154818151, content=<a href='/topic/show?id=48b98e537f' target=_blank style='color:#2F92EE;'>#Herceptin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8753, encryptionId=48b98e537f, topicName=Herceptin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ecc14021123, createdName=minhuang75_72521588, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312454, encodeId=a550312454f3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 06 07:28:40 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312057, encodeId=79e531205efd, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri May 04 22:57:02 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312047, encodeId=cb5531204e10, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 04 22:36:58 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2019-03-15 gj0742

    #Herzuma#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=333408, encodeId=43973334089b, content=不错的文章，值得学习和借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6R7YL2c7UHBd9dTQlxwPXnib6Ns6m6boxy2iaaXKuT8vNMCc9OnThlsMmtEicgwuMyMHTLhDE41ncldwBzHcgia0QQ/132, createdBy=c0982346683, createdName=余国法, createdTime=Sun Jul 22 16:30:59 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715775, encodeId=10ab1e15775e9, content=<a href='/topic/show?id=094a8e60b3' target=_blank style='color:#2F92EE;'>#Herzuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8760, encryptionId=094a8e60b3, topicName=Herzuma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=838832043195, createdName=gj0742, createdTime=Fri Mar 15 23:58:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313298, encodeId=4a013132985f, content=[, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Wed May 09 00:17:03 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339082, encodeId=35f613390822f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412911, encodeId=04091412911c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548181, encodeId=9bf5154818151, content=<a href='/topic/show?id=48b98e537f' target=_blank style='color:#2F92EE;'>#Herceptin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8753, encryptionId=48b98e537f, topicName=Herceptin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ecc14021123, createdName=minhuang75_72521588, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312454, encodeId=a550312454f3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 06 07:28:40 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312057, encodeId=79e531205efd, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri May 04 22:57:02 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312047, encodeId=cb5531204e10, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 04 22:36:58 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-09 121ff658m46暂无昵称

    [

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=333408, encodeId=43973334089b, content=不错的文章，值得学习和借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6R7YL2c7UHBd9dTQlxwPXnib6Ns6m6boxy2iaaXKuT8vNMCc9OnThlsMmtEicgwuMyMHTLhDE41ncldwBzHcgia0QQ/132, createdBy=c0982346683, createdName=余国法, createdTime=Sun Jul 22 16:30:59 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715775, encodeId=10ab1e15775e9, content=<a href='/topic/show?id=094a8e60b3' target=_blank style='color:#2F92EE;'>#Herzuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8760, encryptionId=094a8e60b3, topicName=Herzuma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=838832043195, createdName=gj0742, createdTime=Fri Mar 15 23:58:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313298, encodeId=4a013132985f, content=[, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Wed May 09 00:17:03 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339082, encodeId=35f613390822f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412911, encodeId=04091412911c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548181, encodeId=9bf5154818151, content=<a href='/topic/show?id=48b98e537f' target=_blank style='color:#2F92EE;'>#Herceptin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8753, encryptionId=48b98e537f, topicName=Herceptin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ecc14021123, createdName=minhuang75_72521588, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312454, encodeId=a550312454f3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 06 07:28:40 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312057, encodeId=79e531205efd, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri May 04 22:57:02 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312047, encodeId=cb5531204e10, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 04 22:36:58 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-06 drwjr

    #仿制药#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=333408, encodeId=43973334089b, content=不错的文章，值得学习和借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6R7YL2c7UHBd9dTQlxwPXnib6Ns6m6boxy2iaaXKuT8vNMCc9OnThlsMmtEicgwuMyMHTLhDE41ncldwBzHcgia0QQ/132, createdBy=c0982346683, createdName=余国法, createdTime=Sun Jul 22 16:30:59 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715775, encodeId=10ab1e15775e9, content=<a href='/topic/show?id=094a8e60b3' target=_blank style='color:#2F92EE;'>#Herzuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8760, encryptionId=094a8e60b3, topicName=Herzuma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=838832043195, createdName=gj0742, createdTime=Fri Mar 15 23:58:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313298, encodeId=4a013132985f, content=[, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Wed May 09 00:17:03 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339082, encodeId=35f613390822f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412911, encodeId=04091412911c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548181, encodeId=9bf5154818151, content=<a href='/topic/show?id=48b98e537f' target=_blank style='color:#2F92EE;'>#Herceptin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8753, encryptionId=48b98e537f, topicName=Herceptin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ecc14021123, createdName=minhuang75_72521588, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312454, encodeId=a550312454f3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 06 07:28:40 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312057, encodeId=79e531205efd, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri May 04 22:57:02 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312047, encodeId=cb5531204e10, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 04 22:36:58 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-06 ms9474365431325850

    #欧洲#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=333408, encodeId=43973334089b, content=不错的文章，值得学习和借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6R7YL2c7UHBd9dTQlxwPXnib6Ns6m6boxy2iaaXKuT8vNMCc9OnThlsMmtEicgwuMyMHTLhDE41ncldwBzHcgia0QQ/132, createdBy=c0982346683, createdName=余国法, createdTime=Sun Jul 22 16:30:59 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715775, encodeId=10ab1e15775e9, content=<a href='/topic/show?id=094a8e60b3' target=_blank style='color:#2F92EE;'>#Herzuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8760, encryptionId=094a8e60b3, topicName=Herzuma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=838832043195, createdName=gj0742, createdTime=Fri Mar 15 23:58:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313298, encodeId=4a013132985f, content=[, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Wed May 09 00:17:03 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339082, encodeId=35f613390822f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412911, encodeId=04091412911c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548181, encodeId=9bf5154818151, content=<a href='/topic/show?id=48b98e537f' target=_blank style='color:#2F92EE;'>#Herceptin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8753, encryptionId=48b98e537f, topicName=Herceptin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ecc14021123, createdName=minhuang75_72521588, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312454, encodeId=a550312454f3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 06 07:28:40 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312057, encodeId=79e531205efd, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri May 04 22:57:02 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312047, encodeId=cb5531204e10, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 04 22:36:58 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-06 grace5701

    #生物仿制药#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=333408, encodeId=43973334089b, content=不错的文章，值得学习和借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6R7YL2c7UHBd9dTQlxwPXnib6Ns6m6boxy2iaaXKuT8vNMCc9OnThlsMmtEicgwuMyMHTLhDE41ncldwBzHcgia0QQ/132, createdBy=c0982346683, createdName=余国法, createdTime=Sun Jul 22 16:30:59 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715775, encodeId=10ab1e15775e9, content=<a href='/topic/show?id=094a8e60b3' target=_blank style='color:#2F92EE;'>#Herzuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8760, encryptionId=094a8e60b3, topicName=Herzuma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=838832043195, createdName=gj0742, createdTime=Fri Mar 15 23:58:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313298, encodeId=4a013132985f, content=[, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Wed May 09 00:17:03 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339082, encodeId=35f613390822f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412911, encodeId=04091412911c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548181, encodeId=9bf5154818151, content=<a href='/topic/show?id=48b98e537f' target=_blank style='color:#2F92EE;'>#Herceptin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8753, encryptionId=48b98e537f, topicName=Herceptin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ecc14021123, createdName=minhuang75_72521588, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312454, encodeId=a550312454f3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 06 07:28:40 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312057, encodeId=79e531205efd, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri May 04 22:57:02 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312047, encodeId=cb5531204e10, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 04 22:36:58 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-06 minhuang75_72521588

    #Herceptin#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=333408, encodeId=43973334089b, content=不错的文章，值得学习和借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6R7YL2c7UHBd9dTQlxwPXnib6Ns6m6boxy2iaaXKuT8vNMCc9OnThlsMmtEicgwuMyMHTLhDE41ncldwBzHcgia0QQ/132, createdBy=c0982346683, createdName=余国法, createdTime=Sun Jul 22 16:30:59 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715775, encodeId=10ab1e15775e9, content=<a href='/topic/show?id=094a8e60b3' target=_blank style='color:#2F92EE;'>#Herzuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8760, encryptionId=094a8e60b3, topicName=Herzuma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=838832043195, createdName=gj0742, createdTime=Fri Mar 15 23:58:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313298, encodeId=4a013132985f, content=[, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Wed May 09 00:17:03 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339082, encodeId=35f613390822f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412911, encodeId=04091412911c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548181, encodeId=9bf5154818151, content=<a href='/topic/show?id=48b98e537f' target=_blank style='color:#2F92EE;'>#Herceptin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8753, encryptionId=48b98e537f, topicName=Herceptin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ecc14021123, createdName=minhuang75_72521588, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312454, encodeId=a550312454f3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 06 07:28:40 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312057, encodeId=79e531205efd, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri May 04 22:57:02 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312047, encodeId=cb5531204e10, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 04 22:36:58 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-06 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=333408, encodeId=43973334089b, content=不错的文章，值得学习和借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6R7YL2c7UHBd9dTQlxwPXnib6Ns6m6boxy2iaaXKuT8vNMCc9OnThlsMmtEicgwuMyMHTLhDE41ncldwBzHcgia0QQ/132, createdBy=c0982346683, createdName=余国法, createdTime=Sun Jul 22 16:30:59 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715775, encodeId=10ab1e15775e9, content=<a href='/topic/show?id=094a8e60b3' target=_blank style='color:#2F92EE;'>#Herzuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8760, encryptionId=094a8e60b3, topicName=Herzuma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=838832043195, createdName=gj0742, createdTime=Fri Mar 15 23:58:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313298, encodeId=4a013132985f, content=[, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Wed May 09 00:17:03 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339082, encodeId=35f613390822f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412911, encodeId=04091412911c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548181, encodeId=9bf5154818151, content=<a href='/topic/show?id=48b98e537f' target=_blank style='color:#2F92EE;'>#Herceptin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8753, encryptionId=48b98e537f, topicName=Herceptin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ecc14021123, createdName=minhuang75_72521588, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312454, encodeId=a550312454f3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 06 07:28:40 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312057, encodeId=79e531205efd, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri May 04 22:57:02 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312047, encodeId=cb5531204e10, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 04 22:36:58 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-04 131****2916

    不错的文章值得推荐

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=333408, encodeId=43973334089b, content=不错的文章，值得学习和借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6R7YL2c7UHBd9dTQlxwPXnib6Ns6m6boxy2iaaXKuT8vNMCc9OnThlsMmtEicgwuMyMHTLhDE41ncldwBzHcgia0QQ/132, createdBy=c0982346683, createdName=余国法, createdTime=Sun Jul 22 16:30:59 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715775, encodeId=10ab1e15775e9, content=<a href='/topic/show?id=094a8e60b3' target=_blank style='color:#2F92EE;'>#Herzuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8760, encryptionId=094a8e60b3, topicName=Herzuma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=838832043195, createdName=gj0742, createdTime=Fri Mar 15 23:58:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313298, encodeId=4a013132985f, content=[, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Wed May 09 00:17:03 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261405, encodeId=e7e7126140555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339082, encodeId=35f613390822f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412911, encodeId=04091412911c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548181, encodeId=9bf5154818151, content=<a href='/topic/show?id=48b98e537f' target=_blank style='color:#2F92EE;'>#Herceptin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8753, encryptionId=48b98e537f, topicName=Herceptin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ecc14021123, createdName=minhuang75_72521588, createdTime=Sun May 06 12:58:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312454, encodeId=a550312454f3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun May 06 07:28:40 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312057, encodeId=79e531205efd, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri May 04 22:57:02 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312047, encodeId=cb5531204e10, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri May 04 22:36:58 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-05-04 1e1b8538m79(暂无匿称)

    不错的文章值得拥有

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

CHMP建议批准罗氏皮下注射剂型Herceptin用于HER2阳性乳腺癌

罗氏6月28日宣布，皮下注射剂型赫赛汀（Herceptin）获得了欧盟委员会（EC）人用医药产品委员会（CHMP）的积极意见。CHMP建议批准皮下注射剂型Herceptin用于HER2阳性乳腺癌患者的治疗。 目前，Herceptin通过静脉注射给药，耗时30-90分钟。皮下注射剂型Herceptin则通过皮下注射给药，耗时仅为2-5分钟。 CHMP的积极意见是基于关键性III期HannaH

Herceptin 在HER2+乳腺癌的辅助和新辅助治疗

Herceptin 在HER2+乳腺癌的辅助和新辅助治疗